Peptide RX

back to claim graph

proof receipt / target

SIRT1

NAD-dependent deacetylase sirtuin-1

grade B status longevity receipt e0f340724216 proof 33%

what this node claims

SIRT1

NAD-dependent deacetylase sirtuin-1

Open source surface

vertical proof spine

  1. 01 SIRT1 target / grade B / 70% 1 debt
  2. 02 SIRT1 WT fold / grade B / 54% 3 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 24%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    sirtuin
    functional sites
      gene symbol
      SIRT1
      go terms
        uniprot
        Q96EB6

        AlphaFold metrics visual

        Low-confidence regions present

        65.0

        747 residues / min 24.66 / max 98.88 / source alphafold db

        PAE matrix for linked target
        Very high 36.9% 276 residues / >=90
        Confident 13.0% 97 residues / 70-89
        Low 3.5% 26 residues / 50-69
        Very low 46.6% 348 residues / <50

        weak structural context; downstream claims should be conservative

        Near-complete coverage / observed 747 of 747 residues.

        • residues 1-148 / mean 37.74
        • residues 517-630 / mean 36.16
        • residues 660-747 / mean 37.45
        • residues 155-177 / mean 48.56
        proof debt register

        Visible limits, not hidden cleanup.

        24%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:1dbe24d9-c749-41b4-b88b-0046388348b5 -> fold:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f folds_to / B / 0.65

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.